Device Trial Radar · NCT05886894
Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses
Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
351
Actual
Start
Aug 8, 2023
Primary completion
Jun 20, 2025
Study completion Jun 20, 2025
Sponsor
- Lead sponsor
- Alcon ResearchNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix plus HydraGlyde Multifocal soft contact lenses in a real-world setting when worn as daily wear or extended (overnight) wear.
Conditions
- Refractive Errors
Interventions
Lotrafilcon B multifocal soft contact lensesDevice
Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
Comfilcon A multifocal soft contact lensesDevice
Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
Primary outcomes
What the sponsor says the trial is designed to measure.
- Distance visual acuity at 1 year - Daily WearTime frame: Year 1
- Near visual acuity at 1 year - Daily WearTime frame: Year 1
- Distance visual acuity at 3 years - Extended WearTime frame: Year 3
5 more outcomes with a free account
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Complete Family Vision Care
San Diego, California
Pearle Vision
Jacksonville, Florida
Jackson Health Community Center
Miami, Florida
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.